Innovating Works

BVS

Desconocido
TRIC-TB: Boosting Ethionamide efficacy and lowering the dose with a small molecule transcriptional modulators... BIOVERSYS AG tramitó un H2020: H2020-JTI-IMI2-2018-16-single-stage Tuberculosis (TB) is the world’s leading infectious disease. It killed 1.7 million people in 2016 and 10.4 million people developed active T...
2019-05-28 - 2024-02-29 | Financiado
Train2Target: An integrated mulTidisciplinary appRoach towards a new generAtIon of aNtibiotics Targeting function... BIOVERSYS AG participó en un H2020: H2020-MSCA-ITN-2016 Train2Target is a multidisciplinary European Training Network built to address the challenge of the discovery of alternative antimicrobials....
2016-08-31 - 2020-12-31 | Financiado
TRANSLOCATION: MOLECULAR BASIS OF ANTIBIOTIC TRANSLOCATION BIOVERSYS AG participó en un FP7: Multidrug resistant bacteria are now ubiquitous in both hospitals and the larger community. Drug-resistant pathogens are becoming increasing...
Financiado
* Datos extraídos de la documentos o webs disponibles en diferentes organismos públicos.